查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464700

同種異體細胞治療市場：按類型、應用和最終用途 - 2024-2030 年全球預測

Allogeneic Cell Therapy Market by Type, Application, End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

異體細胞治療市場規模預計2023年為20.4億美元，2024年達23.1億美元，預計2030年將達到50.8億美元，複合年成長率為13.90%。

同種異體細胞療法是一種醫療程序，將來自一名健康捐贈者的細胞移植到多名患者體內，以幫助治療多種疾病，包括某些癌症、自體免疫疾病和心臟病。基因工程、細胞加工和培養技術的進步顯著提高了同種異體細胞療法的功效和安全性，推動了市場成長。癌症、自體免疫疾病和心血管疾病在全球的盛行率不斷上升，推動了對同種異體細胞療法等創新治療方法的需求。在全球範圍內，有利的政府政策和細胞治療方法研究資金的增加正在加速市場擴張。然而，開發和實施同種異體細胞療法的高昂成本限制了更廣泛的患者群體的使用。需要免疫抑制劑來避免免疫排斥和副作用仍然是市場成長的主要挑戰。此外，旨在改善細胞來源、儲存和擴充性的持續研究為市場成長提供了巨大的機會。開發適合個別患者情況的同種異體細胞治療解決方案可能為個人化醫療開闢新途徑。

主要市場統計
基準年[2023] 20.4億美元
預測年份 [2024] 23.1億美元
預測年份 [2030] 50.8億美元
複合年成長率（%） 13.90%

發炎和免疫調節作用擴大了間質幹細胞療法的採用

嵌合體抗原受體T細胞療法（CAR-T）是引入特異性標靶癌細胞的嵌合體抗原受體，提供個人化的癌症治療方法。 CAR-T細胞療法主要用於某些類型的血癌，包括非何傑金氏淋巴瘤和急性淋巴性白血病，以改善治療結果。造血幹細胞移植涉及移植供體（異體）的幹細胞，以健康的幹細胞取代受損的骨髓。當其他治療方法無效時，造血幹細胞移植是某些白血病、淋巴瘤和遺傳性血液疾病患者治療方法計畫的一部分。誘導性多功能幹細胞療法 (iPSC) 是將皮膚和血球重新編程為胚胎樣多功能狀態。 iPSC技術主要應用於再生醫學、疾病模型和藥物發現。間質幹細胞療法具有分化成各種細胞類型的能力，並具有發炎和免疫調節作用。

應用：徹底改變其在改善同種異體細胞療法和器官移植手術中的作用

同種異體細胞療法大大改善了白血病和淋巴瘤等血液疾病的治療。在腫瘤治療中，同種異體細胞療法利用免疫系統攻擊癌細胞的能力，用於對抗多種癌症。

再生醫學是同種異體細胞療法中最令人興奮的領域，專注於修復、替換和再生人體細胞、器官和組織以及恢復正常功能。同種異體細胞療法在固態器官移植中也發揮關鍵作用，特別是在降低移植排斥風險和終生免疫抑制的需求方面。

區域洞察

美洲，特別是美國和加拿大，在強勁投資、尖端研究和日益促進生物技術創新的法規環境的推動下，處於同種異體細胞治療行業的前沿。智慧財產權的發展，例如細胞處理技術和反應器設計專利的穩定取得，顯示了美洲地區市場的活力。在歐盟（EU），政府和私人對再生醫學（包括異體細胞療法）給予了強烈的支持。德國、英國和法國等國家尤其活躍，開展了大量臨床試驗和研究舉措，並從鼓勵創新同時確保病人安全的法律規範中受益。阿拉伯聯合大公國和沙烏地阿拉伯等中東國家正大力投資醫療基礎設施，並表示有興趣引進先進的醫療方法，包括細胞療法。非洲地區更加多元化，南非在再生醫學的研究和興趣方面處於領先地位。在亞太地區，中國在政府對生物技術研究的大力支持下正在取得顯著進展。日本和印度享有再生醫學先驅的聲譽，並得到有利的監管政策的支持，以快速開發有前景的治療方法。

FPNV定位矩陣

FPNV定位矩陣對於評估同種異體細胞治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對同種異體細胞治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.同種異體細胞治療市場的市場規模與預測是多少？

2.在同種異體細胞治療市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.同種異體細胞治療市場的技術趨勢和法規結構是什麼？

4.同種異體細胞治療市場主要廠商的市場佔有率是多少？

5. 進入同種異體細胞治療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症、自體免疫疾病和心血管疾病的發生率增加
      • 有利的政府政策和增加細胞治療方法研究資金
    • 抑制因素
      • 同種異體細胞療法開發和管理的複雜法規環境
    • 機會
      • 開發個人化同種異體細胞治療解決方案
      • 探索神經退化性疾病和心臟病的新治療方法
    • 任務
      • 免疫排斥和相容性問題
  • 市場區隔分析
    • 類型：間間質幹細胞療法因其發炎和免疫調節特性而被擴大採用
    • 應用：徹底改變同種異體細胞療法在器官移植治療和改善中的作用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章同種異體細胞治療市場：依類型

  • 嵌合體抗原受體T細胞療法
  • 造血幹細胞移植
  • 誘導性多功能幹細胞治療
  • 間質幹細胞治療

第7章同種異體細胞治療市場：依應用分類

  • 血液疾病
  • 腫瘤學
  • 再生醫學
  • 固態器官移植

第8章同種異體細胞治療市場：依最終用途

  • 生物技術和製藥公司
  • 醫院/診所
  • 調查機構

第9章美洲同種異體細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太同種異體細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲同種異體細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭場景分析
    • Getinge 與 CellRev 之間的策略合作夥伴關係徹底改變了製造業
    • 開創性協議將促進全球獲得 StemCyte 突破性的臍帶血衍生細胞療法
    • Gamida Cell 的 Omisirge 療法核准FDA 批准，成為血癌治療的突破
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-CA100284D019

[187 Pages Report] The Allogeneic Cell Therapy Market size was estimated at USD 2.04 billion in 2023 and expected to reach USD 2.31 billion in 2024, at a CAGR 13.90% to reach USD 5.08 billion by 2030.

Allogeneic cell therapy involves medical treatments wherein cells are transferred from a single healthy donor to multiple patients to help treat various diseases, including certain cancers, autoimmune diseases, and heart conditions. Ongoing advances in genetic engineering, cell processing, and culturing techniques have significantly enhanced the efficacy and safety of allogeneic cell therapies, fueling market growth. The growing incidence of cancers, autoimmune diseases, and cardiovascular conditions globally drives the demand for innovative treatments such as allogeneic cell therapy. Favorable government policies worldwide and increased funding for research in cell-based therapies have accelerated market expansion. However, high costs associated with the development and administration of allogeneic cell therapies limit accessibility for a broader patient base. Immune rejection and the need for immunosuppressants to avoid adverse reactions remain significant challenges for market growth. Moreover, continuous research aiming at improving cell sourcing, preservation, and scalability presents substantial opportunities for market growth. Developing tailored allogeneic cell therapy solutions catering to individual patient profiles may open new avenues for personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 2.04 billion
Estimated Year [2024] USD 2.31 billion
Forecast Year [2030] USD 5.08 billion
CAGR (%) 13.90%

Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties

Chimeric antigen receptor T cell therapy (CAR-T) involves the introduction of a chimeric antigen receptor that specifically targets cancer cells, providing a personalized approach to cancer therapy. CAR-T cell therapy is primarily employed for certain types of blood cancers including non-Hodgkin lymphoma and acute lymphoblastic leukemia for improved outcomes. Hematopoietic stem cell transplantation is responsible for the transplantation of stem cells from a donor (allogeneic) to replace damaged bone marrow with healthy stem cells. Hematopoietic stem cell transplantation is the treatment of choice for patients with certain leukemias, lymphomas, and genetic blood disorders when other treatments are not effective or as a part of the treatment plan. Induced pluripotent stem cell therapy (iPSC) is derived from skin or blood cells reprogrammed back into an embryonic-like pluripotent state. iPSC technology is primarily utilized for regenerative medicine, disease modeling, and drug discovery. Mesenchymal stem cell therapy has the ability to differentiate into various cell types and possesses anti-inflammatory and immunomodulatory properties.

Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures

Allogeneic cell therapy has significantly improved the treatment of hematological disorders, such as leukemia and lymphoma. In oncology therapies, allogeneic cell therapy is utilized to fight against various cancer forms, leveraging the immune system's capacity to attack cancer cells.

Regenerative medicine represents the most exciting areas of allogeneic cell therapy, focusing on repairing, replacing, and regenerating human cells, organs, or tissues to restore normal function. Allogeneic cell therapy also plays a pivotal role in solid organ transplantation, particularly in reducing the risk of transplant rejection and the need for lifelong immunosuppression.

Regional Insights

The Americas, particularly the United States and Canada, are at the forefront of the allogeneic cell therapy industry, driven by robust investments, cutting-edge research, and a supportive regulatory environment that is increasingly conducive to innovation in biotechnology. Intellectual property developments, typified by a steady stream of patents related to cell processing techniques and bioreactor designs, demonstrate the vibrancy of the market in the Americas region. The European Union observes strong government and private support for regenerative medicine, including allogeneic cell therapy. Countries such as Germany, the United Kingdom, and France have been particularly active, with numerous clinical trials and research initiatives, and also benefit from a regulatory framework encouraging innovation while ensuring patient safety. Middle East countries such as the United Arab Emirates and Saudi Arabia, are investing significantly in healthcare infrastructure and have shown interest in adopting advanced medical treatments, including cell therapies. The African region is more diverse, with South Africa leading in terms of research and interest in regenerative medicine. In the APAC region, China has made remarkable strides, with substantial government backing for biotechnology research. Japan and India have a well-established reputation for pioneering regenerative medicine, supported by favorable regulatory policies to fast-track promising therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Allogeneic Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Allogeneic Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Chimeric Antigen Receptor T Cell Therapy
    • Hematopoietic Stem Cell Transplantation
    • Induced Pluripotent Stem Cell Therapy
    • Mesenchymal Stem Cell Therapy
  • Application
    • Hematological Disorders
    • Oncology
    • Regenerative Medicine
    • Solid Organ Transplantation
  • End-Use
    • Biotechnology & Pharmaceutical Companies
    • Hospitals & Clinics
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Allogeneic Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Allogeneic Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Allogeneic Cell Therapy Market?

4. What is the market share of the leading vendors in the Allogeneic Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Allogeneic Cell Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
      • 5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of personalized allogeneic cell therapy solutions
      • 5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Immune rejection and compatibility issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
    • 5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Allogeneic Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric Antigen Receptor T Cell Therapy
  • 6.3. Hematopoietic Stem Cell Transplantation
  • 6.4. Induced Pluripotent Stem Cell Therapy
  • 6.5. Mesenchymal Stem Cell Therapy

7. Allogeneic Cell Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Hematological Disorders
  • 7.3. Oncology
  • 7.4. Regenerative Medicine
  • 7.5. Solid Organ Transplantation

8. Allogeneic Cell Therapy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biotechnology & Pharmaceutical Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Research Institutes

9. Americas Allogeneic Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Allogeneic Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Allogeneic Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
    • 12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
    • 12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 289. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 290. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023